Abstract
Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 105-114 |
| Number of pages | 10 |
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 82 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Jan 2015 |
| Externally published | Yes |
Fingerprint
Explore the research areas of 'Denosumab: A novel antiresorptive drug for osteoporosis'.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver